Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms

Authors :: Jean-Christophe Ianotto
Laurent Misery
Vincent Rebière
Marie Orliaguet
Jean-Richard Eveillard
Sylvie Boisramé
Marie-Anne Couturier
Gaelle Guillerm
Brigitte Pan-Petesch
Marie-Caroline Le Bousse-Kerdilès
Eric Lippert
Source :: eJHaem. 1:350-352
Publication Year :: 2020
Publisher :: Wiley, 2020.

Subjects :: Oncology
medicine.medical_specialty
Ruxolitinib
business.industry
Pegylated interferon
Internal medicine
medicine
business
medicine.drug

Full Text Access

Tools